Ultragenyx Pharmaceutical Inc. announced that it has appointed Howard Horn as executive vice president effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. Mr. Horn joins Ultragenyx from Vir Biotechnology, where he served as CFO from 2017 to 2023.

As a member of Vir’s founding management team, he successfully led a series of private and public financings and executed multiple foundational transactions that supported the rapid transformation of Vir to a public, commercial-stage organization. Prior to Vir, Mr. Horn served as vice president, business planning at Biogen where he led Biogen's resource allocation processes across all functions and regions. Mr. Horn also served as Biogen's vice president, strategic corporate finance, where he led Biogen's corporate capital allocation processes.

Previously, he held positions of increasing responsibility as a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Company, and as an equity research analyst in the Life Sciences group at UBS Group AG. Mr. Horn received his B.A. in Economics from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania.